Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes
It is still important for patients taking GLP-1 medication to limit muscle wasting through exercise and high-quality protein. Losing muscle can lower metabolic rate and physical strength
This increase in energy helps combat fatigue, making it easier to stay active and motivated to exercise, which, in turn, burns more calories
One side effect of how well they work is rarely talked about upfront: eating significantly less, consistently, over months, can mean missing nutrients you'd normally get from a fuller diet
Epithalon Within a Broader Longevity Protocol No single peptide addresses all aspects of biological aging
You need transparent pricing without account creation